UNJHA FORMULATIONS LTD.
Latest filings
Next results: Thu, 5 Nov · Financial Results- Board to approve half-year results on November 5 · Results
- Board to approve Q2 FY2027 unaudited results · Results
- Half-yearly share transfer compliance certified for September 2026 · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations from its registered office in Sidhpur, North Gujarat, generating Rs 15.5852 crore of revenue in FY26, up roughly 12% from Rs 13.86 crore the prior year. The single biggest cost line is raw materials at 77% of revenue, with the company approving related-party purchases of psyllium husk from Urvesh and Company up to Rs 200 lakhs, signalling that ingredient is a key input. Employee cost runs at 6% of revenue and other operating expenses at 10.7%, while depreciation (0.9%) and capex (0%) are negligible. Profit after tax rose to Rs 0.7047 crore (a 72.8% increase) on an FY26 ebitda margin of 7.08%. The company carries no long-term borrowings, holds Rs 164.48 lakhs of cash, and reported net worth of Rs 384.34 lakhs as of 31 March 2026.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from UNJHA FORMULATIONS LTD.'s filed financials and exchange disclosures
What does UNJHA FORMULATIONS LTD. do?
UNJHA FORMULATIONS LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is UNJHA FORMULATIONS LTD. profitable?
Yes. Over the trailing twelve months UNJHA FORMULATIONS LTD. reported a net profit of ₹0.70 Cr on revenue of ₹16 Cr.
Does UNJHA FORMULATIONS LTD. pay a dividend?
Not in the latest reported year — UNJHA FORMULATIONS LTD.'s dividend payout for FY26 was nil.
Is UNJHA FORMULATIONS LTD. debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹1.64 Cr of cash.
Is UNJHA FORMULATIONS LTD. expensive compared with its peers?
On trailing P/E, UNJHA FORMULATIONS LTD. ranks 39 of 158 in Pharmaceuticals — cheaper than 76% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the UNJHA FORMULATIONS LTD. share price move in a day?
On a typical session UNJHA FORMULATIONS LTD. moves 2.08% — that is the median absolute close-to-close move across its last 265 trading days. MarketPing measures each filing's price reaction against it.
When are UNJHA FORMULATIONS LTD.'s next results?
Financial Results on Thu, 5 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track UNJHA FORMULATIONS LTD.'s announcements?
Every NSE and BSE filing by UNJHA FORMULATIONS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.